Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Eno Inyang, PharmD, BCPS, Nikhil C. Munshi, MD, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136342

Published: 2020

Journal Articles

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Shawn O. Streeter, PharmD, Omar Nadeem, MD, Paul G. Richardson, MD, Jacob P. Laubach, MD, Clifton C. Mo, MD, Kimberly Noonan, RN, NP, AOCN, Mary McKenney, NP, Tina Flaherty, ANP-BC, AOCN, Virginia Dalton, MS, APRN, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-143385

Published: 2020

Journal Articles

Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study

Grace Hwang, PharmD, Audrea Szabatura, PharmD, Houry Leblebjian, PharmD, BCOP, Anil Aktas-Samur, PhD, Jacob P. Laubach, MD, Aric D. Parnes, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-140175

Published: 2020

Journal Articles

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, MD, Robert Allyn Redd, MS, Jeffrey Matous, Philippe Armand, MD PhD, Erica N Boswell, BS, Stacey Chuma, BSN, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Jorge J. Castillo, MD, Jacob P. Laubach, MD, Claudia E. Paba-Prada, MD, Kenneth C. Anderson, MD, Paul G. Richardson, Edie A. Weller, PhD, Steven P Treon, MD MA, PhD

Blood (2014) 124 (21): 3081.

https://doi.org/10.1182/blood.V124.21.3081.3081

Published: 2014

Journal Articles

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Irene M. Ghobrial, MD, Jacob P. Laubach, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Erica N Boswell, BS, Patrick M Henrick, MPH, Abdel Kareem Azab, Bpharm, PhD, Courtney Hanlon, Stacey Chuma, BSN, Houry Leblebjian, PharmD, BCOP, Kimberly Noonan, RN, NP, AOCN, Megan H. MacNabb, BA, Diane Warren, Philippe Armand, MD PhD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Robert L Schlossman, MD, Kenneth C. Anderson, MD, Paul G. Richardson

Blood (2014) 124 (21): 5777.

https://doi.org/10.1182/blood.V124.21.5777.5777

Published: 2014

Journal Articles

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Patrick Mostyn, Farzana Masood, Paul G. Richardson, MD, Steven Peter Treon, MD, MA, PhD, Jeffrey Matous, MD

Blood (2013) 122 (21): 4402.

https://doi.org/10.1182/blood.V122.21.4402.4402

Published: 2013

Journal Articles

Assessment Of Drug Toxicity In Patients With and Without Renal Impairment Receiving Lenalidomide At a Large Academic Institution

Houry Leblebjian, PharmD, BCOP, Wanling Xie, MS, Paul G. Richardson, MD, Irene M. Ghobrial, MD, Christy Harris, PharmD, BCPS, BCOP, Robert L Schlossman, MD, Claudia E. Paba-Prada, MD, Nikhil C. Munshi, MD, Sylvia Bartel, R.Ph., M.H.P., Kenneth C. Anderson, MD, Edie A. Weller, PhD, Jacob P. Laubach, MD

Blood (2013) 122 (21): 1977.

https://doi.org/10.1182/blood.V122.21.1977.1977

Published: 2013

NARROW

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Assessment Of Drug Toxicity In Patients With and Without Renal Impairment Receiving Lenalidomide At a Large Academic Institution

Email alerts

ASH Publications

American Society of Hematology

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study

Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia

Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Assessment Of Drug Toxicity In Patients With and Without Renal Impairment Receiving Lenalidomide At a Large Academic Institution

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only